deal_title stringlengths 15 233 | data_source listlengths 1 6 | principle_org listlengths 1 3 ⌀ | partner_org listlengths 1 4 ⌀ | deal_project listlengths 1 9 ⌀ | deal_type listlengths 1 3 ⌀ | deal_value listlengths 1 4 ⌀ | territory_included listlengths 1 23 ⌀ |
|---|---|---|---|---|---|---|---|
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections | [
"News",
"Company_Website"
] | [
"Anacor Pharmaceuticals"
] | [
"葛兰素史克制药"
] | [
{
"name": " GSK2251052",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "15百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "15.00"
}
] | null |
ViVerita Therapeutics Announces Research Collaboration with Boehringer Ingelheim to Accelerate Discovery of Novel Cancer Targets | [
"PRNewswire"
] | [
"ViVerita Therapeutics Inc"
] | [
"Boehringer Ingelheim"
] | [
{
"name": "Novel Cancer Targets",
"type": "Technology/Platform"
}
] | [
"Collaboration"
] | null | null |
Ligand Pharmaceuticals acquires Ab Initio Biotherapeutics | [
"NEWS"
] | [
"Ab Initio Biotherapeutics"
] | [
"Ligand Pharmaceuticals"
] | [
{
"name": "Ab Initio Biotherapeutics",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "12,000,000 USD",
"type": "total_value",
"unit": "million dollars",
"value": "12.00"
}
] | null |
海和药物成功召开德立替尼AL3810-202胸腺癌关键性II b期临床试验全国研究者会议 | [
"News"
] | [
"中国科学院上海药物研究所"
] | [
"上海海和药物研究开发股份有限公司"
] | [
{
"name": "Lucitanib",
"type": "Drug"
}
] | [
"合作"
] | null | [
"中国(含中国内地、香港、澳门、台湾)"
] |
Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb | [
"News"
] | [
"Volastra Therapeutics"
] | [
"百时美施贵宝制药"
] | [
{
"name": "CINtech platform",
"type": "Technology/Platform"
}
] | [
"合作"
] | [
{
"origin_value": "1100百万美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "1100.00"
},
{
"origin_value": "30百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "30.00"
}
] | null |
Bio-Techne and Regulus collaborate to conduct biomarker analysis for RGLS-4326 in ADPKD. | [
"NEWS"
] | [
"Bio-Techne Corp"
] | [
"Regulus Therapeutics Inc"
] | [
{
"phase": "Phase 1 Clinical",
"name": "RGLS-4326",
"type": "Drug"
}
] | [
"合作"
] | null | null |
J&J inks an $835M RNA deal to develop autoimmune drugs with Isis | [
"NEWS",
"Company_Website",
"Company_Website",
"Company_Website"
] | [
"Isis"
] | [
"Johnson & Johnson",
"Janssen Biotech, Inc."
] | [
{
"phase": "Preclinical",
"name": "IONIS-JBI1-2.5Rx",
"type": "Drug"
},
{
"phase": "Pending",
"name": "ION253",
"type": "Drug"
},
{
"name": "new drugs for autoimmune diseases of the gastrointestinal tract",
"type": "Drug"
}
] | [
"License"
] | [
{
"origin_value": "$800 million",
"type": "milestone_payment",
"unit": "million dollars",
"value": "800.0000"
},
{
"origin_value": "$35 million",
"type": "upfront_payment",
"unit": "million dollars",
"value": "35.0000"
}
] | [
"global"
] |
Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib for Treatment | [
"News"
] | [
"安斯泰来制药"
] | [
"Maruho"
] | [
{
"phase": "Phase 3 Clinical",
"name": "peficitinib",
"type": "Drug"
}
] | [
"许可"
] | null | [
"Global"
] |
Adimab Initiates New Therapeutic Discovery Partnership with Innovent | [
"NEWS",
"NEWS"
] | [
"Adimab, LLC"
] | [
"Innovent"
] | [
{
"name": "an antibody-based therapeutic program",
"type": "Drug"
}
] | [
"合作"
] | null | [
"worldwide"
] |
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A | [
"News"
] | [
"AgeX Therapeutics"
] | [
"Sernova"
] | [
{
"name": "UniverCyte(TM) gene technology",
"type": "Technology/Platform"
}
] | [
"许可"
] | null | null |
Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab | [
"Company_Website",
"News",
"News"
] | [
"Biocon Group"
] | [
"Equillium"
] | [
{
"phase": "Approved",
"name": "itolizumab",
"type": "Drug"
}
] | [
"许可",
"投资"
] | null | [
"New Zealand",
"Australia"
] |
Aldeyra Therapeutics acquires Helio Vision | [
"NEWS"
] | [
"Helio Vision"
] | [
"Aldeyra Therapeutics"
] | [
{
"name": "Helio Vision",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "24,645,296 USD",
"type": "total_value",
"unit": "million dollars",
"value": "24.65"
}
] | null |
Alvogen Korea Holdings acquires Alvogen Korea Co., Ltd. | [
"NEWS"
] | [
"Alvogen Korea Co., Ltd."
] | [
"Alvogen Korea Holdings",
"Lotus Pharmaceutical"
] | [
{
"name": "Alvogen Korea Co., Ltd.",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "23,777,971 USD",
"type": "total_value",
"unit": "million dollars",
"value": "23.78"
}
] | null |
Adare Pharma Solutions, Inc. acquires Frontida BioPharm, Inc. | [
"NEWS"
] | [
"Frontida BioPharm, Inc."
] | [
"Adare Pharma Solutions, Inc.",
"Frazier Management",
"Thomas H Lee Partners"
] | [
{
"name": "Frontida BioPharm, Inc.",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Sepracor, Inc. Acquires Exclusive U.S. Rights to Nycomed's ALVESCO(R) HFA and OMNARIS AQ Products as Well as Ciclesonide Pipeline | [
"News"
] | [
"奈科明制药"
] | [
"Sunovion Pharmaceuticals"
] | [
{
"phase": "Approved",
"name": "ciclesonide",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "150百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "150.00"
}
] | [
"United States"
] |
Immunocore and Genentech enter strategic alliance to develop ImmTACs for multiple cancer targets | [
"NEWS",
"NEWS"
] | [
"Immunocore"
] | [
"基因泰克"
] | [
{
"phase": "Preclinical",
"name": "IMC-C103C",
"type": "Drug"
}
] | [
"合作"
] | [
{
"origin_value": "100百万美元",
"type": "total_value",
"unit": "million dollars",
"value": "100.00"
}
] | null |
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation | [
"NEWS"
] | [
"康泰伦特药业"
] | [
"Melt Pharmaceuticals"
] | [
{
"name": "Zydis® orally disintegrating tablet fast-dissolve technology",
"type": "Technology/Platform"
}
] | [
"合作"
] | null | null |
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline | [
"GlobeNewswire",
"NEWS",
"NEWS",
"NEWS"
] | [
"Inhibrx, Inc."
] | [
"Sanofi"
] | [
{
"phase": "phase 2 clinical",
"name": "INBRX-101",
"type": "Drug"
},
{
"name": "Inhibrx, Inc.",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "$2.196 billion",
"type": "total_value",
"unit": "million dollars",
"value": "2196.00"
}
] | null |
EUROAPI SA offers to acquire BianoScience GmbH | [
"NEWS"
] | [
"BianoScience GmbH"
] | [
"EUROAPI SA"
] | [
{
"name": "BianoScience GmbH",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "10,805,499 USD",
"type": "total_value",
"unit": "million dollars",
"value": "10.81"
}
] | null |
AtriCure acquires SentreHEART | [
"NEWS",
"NEWS"
] | [
"SentreHEART"
] | [
"AtriCure"
] | [
{
"name": "SentreHEART",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "281,397,011 USD",
"type": "total_value",
"unit": "million dollars",
"value": "281.40"
}
] | null |
CRT, Tusk and UCL form immuno-oncology pact | [
"News"
] | [
"Cancer Research Technology"
] | [
"Tusk Therapeutics"
] | [
{
"name": "therapeutic antibodies",
"type": "Drug"
}
] | [
"许可"
] | null | [
"Global"
] |
Verve Therapeutics and Acuitas Therapeutics made a Non-Exclusive License Agreement. | [
"NEWS"
] | [
"Acuitas Therapeutics"
] | [
"Verve Therapeutics"
] | [
{
"name": "LNP Technology",
"type": "Technology/Platform"
}
] | [
"合作"
] | null | null |
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration | [
"NEWS"
] | [
"Zymeworks Inc"
] | [
"LEO Pharma A/S"
] | [
{
"phase": "Discovery",
"name": "bispecific antibodies targeting cytokine-receptor pathways , Zymeworks/Leo",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "475 million 美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "475.00"
},
{
"origin_value": "480 million 美元",
"type": "total_value",
"unit": "million dollars",
"value": "480.00"
},
{
"origin_value": "5 million 美元",
"type": "upfro... | [
"World"
] |
ERT Operating Co. acquires NeuroRx Research, Inc. | [
"NEWS"
] | [
"NeuroRx Research, Inc."
] | [
"ERT Operating Co.",
"Clario Holdings, Inc."
] | [
{
"name": "NeuroRx Research, Inc.",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Acticor Biotech: A +60M€ Regional Development and Commercialisation Agreement Signed with China Medical System Holding Limited® | [
"NEWS"
] | [
"Acticor Biotech"
] | [
"China Medical System Holdings Ltd"
] | [
{
"phase": "Phase 1 Clinical",
"name": "glenzocimab",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "71.54 million 美元",
"type": "total_value",
"unit": "million dollars",
"value": "71.54"
}
] | [
"Asia"
] |
Day One Completes Acquisition of Mersana Therapeutics | [
"GlobeNewswire",
"Company_Website"
] | [
"Mersana Therapeutics"
] | [
"Day One Biopharmaceuticals"
] | [
{
"name": "Mersana Therapeutics",
"type": "Company"
},
{
"phase": "Phase 1 Clinical",
"name": "XMT-2056",
"type": "Drug"
},
{
"phase": "Phase 1 Clinical",
"name": "Emi-Le",
"type": "Drug"
}
] | [
"M&A"
] | [
{
"origin_value": "$285 million",
"type": "total_value",
"unit": "million dollars",
"value": "285.0000"
}
] | null |
SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche | [
"News"
] | [
"SemaThera"
] | [
"罗氏制药"
] | [
{
"phase": "Preclinical",
"name": "novel Semaphorin 3A antagonists",
"type": "Drug"
}
] | [
"许可"
] | null | null |
Orthofix Medical acquires WITTENSTEIN intens | [
"NEWS",
"NEWS"
] | [
"WITTENSTEIN intens"
] | [
"Orthofix Medical"
] | [
{
"name": "WITTENSTEIN intens",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "18,031,022 USD",
"type": "total_value",
"unit": "million dollars",
"value": "18.03"
}
] | null |
LabConnect, Inc. acquires A4P Consulting Ltd. | [
"NEWS"
] | [
"A4P Consulting Ltd."
] | [
"LabConnect, Inc."
] | [
{
"name": "A4P Consulting Ltd.",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Breckenridge Pharmaceutical developed a generic version of Ablysinol in partnership with Andersen Pharma Global | [
"PRNewswire"
] | [
"Breckenridge Pharmaceutical, Inc."
] | [
"Andersen Pharma Global"
] | [
{
"phase": "Approved",
"name": "a generic version of Ablysinol",
"type": "Drug"
}
] | [
"Collaboration"
] | null | null |
Portage Biotech acquires Tarus Therapeutics, Inc. | [
"NEWS"
] | [
"Tarus Therapeutics, Inc."
] | [
"Portage Biotech"
] | [
{
"name": "Tarus Therapeutics, Inc.",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "52,200,333 USD",
"type": "total_value",
"unit": "million dollars",
"value": "52.20"
}
] | null |
RIKEN and Astellas Enter into Worldwide ExclusiveLicensing Agreement for Artificial Adjuvant VectorCell Technology in Oncology | [
"NEWS"
] | [
"RIKEN"
] | [
"Astellas Pharma Inc"
] | [
{
"phase": "Phase 1/2 Clinical",
"name": "ASP-7517",
"type": "Drug"
},
{
"name": "ASP-0739",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "1000 million 日元",
"type": "total_value",
"unit": "million dollars",
"value": "9.41"
}
] | [
"World"
] |
Medix Biochemica Oy Ab acquires CANDOR Bioscience GmbH | [
"NEWS"
] | [
"CANDOR Bioscience GmbH"
] | [
"DevCo Partners Oy",
"Medix Biochemica Oy Ab"
] | [
{
"name": "CANDOR Bioscience GmbH",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
SEJONG MEDICAL Co., Ltd. takes a minority stake in Yozma BMTech Co., Ltd. | [
"NEWS",
"NEWS"
] | [
"Yozma BMTech Co., Ltd."
] | [
"SEJONG MEDICAL Co., Ltd."
] | [
{
"name": "Yozma BMTech Co., Ltd.",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Fosun Pharma Inches Up After Securing Rights to Innovative Alzheimer's Disease Drug in China | [
"NEWS"
] | [
"NeuCo United"
] | [
"Fosun Pharmaceutical Group",
"Fosun Pharma Industry Development"
] | [
{
"phase": "Phase 3 Clinical",
"name": "AR1001",
"type": "Drug"
}
] | [
"License"
] | [
{
"origin_value": "USD20.9 million",
"type": "total_value",
"unit": "million dollars",
"value": "20.9000"
},
{
"origin_value": "USD5.6 million",
"type": "upfront_payment",
"unit": "million dollars",
"value": "5.6000"
}
] | [
"Chinese mainland, Hong Kong, and Macao"
] |
Suan Farma takes a majority stake in Monteloeder SL | [
"NEWS"
] | [
"Monteloeder SL"
] | [
"Suan Farma"
] | [
{
"name": "Monteloeder SL",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
海翔药业与万邦德制药就渐冻症新药研发签订合作协议 交易总额为1.5亿元 | [
"NEWS"
] | [
"万邦德制药"
] | [
"海翔药业"
] | [
{
"phase": "Approved",
"name": "WP205",
"type": "Drug"
}
] | [
"Collaboration"
] | [
{
"origin_value": "3000万元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "4.3013"
},
{
"origin_value": "1.5亿元",
"type": "total_value",
"unit": "million dollars",
"value": "21.5066"
},
{
"origin_value": "1.2亿元",
"type": "upfront_payment",
"unit"... | null |
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System | [
"NEWS"
] | [
"Nascent Biotech, Inc."
] | [
"HypoSpray Pharma"
] | [
{
"phase": "discovery",
"name": "Transdermal Delivery formulation of Pritumumab",
"type": "Drug"
}
] | [
"合作"
] | null | null |
Isis, Zeneca Enter $40M Pact For Cancer Treatments | [
"NEWS"
] | [
"Isis Pharmaceuticals Inc."
] | [
"Zeneca Pharmaceuticals Inc."
] | [
{
"phase": "Discovery",
"name": "antisense-based compounds for cancer",
"type": "Drug"
}
] | [
"Collaboration"
] | [
{
"origin_value": "$40 million",
"type": "total_value",
"unit": "million dollars",
"value": "40.0000"
}
] | [
"worldwide"
] |
Fresenius Kabi completes acquisition of Merck KGaA’s biosimilars business - Fresenius | [
"Company_Website"
] | [
"默克制药"
] | [
"费森尤斯卡比制药"
] | [
{
"name": "Merck KGaA’s biosimilars",
"type": "Drug"
}
] | [
"收购"
] | [
{
"origin_value": "545.7百万美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "545.70"
},
{
"origin_value": "170.26百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "170.26"
}
] | null |
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes | [
"Biospace"
] | [
"Remedium Bio, Inc."
] | [
"Eli Lilly"
] | [
{
"phase": "Discovery",
"name": "gene therapies for Type 2 diabetes and obesity",
"type": "Drug"
}
] | [
"Collaboration"
] | null | null |
SK Biopharmaceuticals expands radiopharmaceutical therapy portfolio with second in-licensed candidate from Wisconsin Alumni Research Foundation | [
"PRNewswire"
] | [
"Wisconsin Alumni Research Foundation"
] | [
"SK Biopharmaceuticals"
] | [
{
"phase": "Preclinical",
"name": "WT-7695",
"type": "Drug"
}
] | [
"License"
] | null | [
"worldwide"
] |
Syncona Investment Management Ltd. acquires Freeline Therapeutics Holdings Ltd. | [
"NEWS",
"NEWS"
] | [
"Freeline Therapeutics Holdings Ltd."
] | [
"Syncona Ltd.",
"Syncona Investment Management Ltd."
] | [
{
"name": "Freeline Therapeutics Holdings Plc",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "12,146,462 USD",
"type": "total_value",
"unit": "million dollars",
"value": "12.15"
}
] | null |
Flex Pharma acquires Salarius Pharmaceuticals LLC | [
"NEWS",
"NEWS"
] | [
"Salarius Pharmaceuticals LLC"
] | [
"Flex Pharma"
] | [
{
"name": "Salarius Pharmaceuticals LLC",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "36,600,000 USD",
"type": "total_value",
"unit": "million dollars",
"value": "36.60"
}
] | null |
SIGA Announces TPOXX® Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets | [
"GlobeNewswire"
] | [
"SIGA Technologies Inc"
] | [
"Meridian Medical Technologies Inc"
] | [
{
"phase": "Approved",
"name": "tecovirimat , SIGA Technologies",
"type": "Drug"
}
] | [
"许可"
] | null | [
"World"
] |
Haemonetics acquires enicor | [
"NEWS"
] | [
"enicor"
] | [
"Haemonetics"
] | [
{
"name": "enicor",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "20,500,000 USD",
"type": "total_value",
"unit": "million dollars",
"value": "20.50"
}
] | null |
Scinai Immunotherapeutics Ltd. acquires Recipharm Israel Ltd. | [
"NEWS"
] | [
"Recipharm Israel Ltd."
] | [
"Scinai Immunotherapeutics Ltd."
] | [
{
"name": "Recipharm Israel Ltd.",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Reig Jofre contributes its know-how in the development ofbiological vaccines to the innovative consortium of Vaxdyn | [
"NEWS"
] | [
"Reig Jofre Group"
] | [
"Vaxdyn SL"
] | [
{
"phase": "Preclinical",
"name": "VXD-001",
"type": "Drug"
},
{
"phase": "Preclinical",
"name": "VXD-004",
"type": "Drug"
},
{
"phase": "Preclinical",
"name": "VXD-002",
"type": "Drug"
}
] | [
"合作"
] | null | null |
An agreement with Fabre-Kramer Pharmaceuticals granting Organon rights to further develop and market gepirone | [
"NEWS"
] | [
"Bristol Myers Squibb Co.",
"Mead Johnson Nutrition Co."
] | [
"Fabre Kramer Pharmaceuticals"
] | [
{
"name": "Gepirone ER",
"type": "Drug"
}
] | [
"收购"
] | null | null |
Odonate Therapeutics licensed patent rights covering tesetaxel from Daiichi Sankyo. | [
"News"
] | [
"第一三共株式会社"
] | [
"Odonate Therapeutics"
] | [
{
"phase": "Phase 2 Clinical",
"name": "tesetaxel",
"type": "Drug"
}
] | [
"许可"
] | null | null |
NOXXON Pharma AG Licenses And Assigns Preclinical Spiegelmer Programs To Aptarion | [
"News"
] | [
"TME PHARMA"
] | [
"Aptarion biotech AG"
] | [
{
"phase": "Preclinical",
"name": "Preclinical Spiegelmer Programs",
"type": "Drug"
}
] | [
"收购"
] | null | null |
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 | [
"NEWS",
"News"
] | [
"Spero Therapeutics Inc"
] | [
"辉瑞制药"
] | [
{
"phase": "Phase 1 Clinical",
"name": "SPR206",
"type": "Drug"
}
] | [
"投资",
"许可"
] | [
{
"origin_value": "80 million 美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "80.00"
}
] | [
"worldwide"
] |
Orthocell Ltd. offers to take a minority stake in Marine Biomedical Pty Ltd. | [
"NEWS"
] | [
"Marine Biomedical Pty Ltd."
] | [
"Orthocell Ltd."
] | [
{
"name": "Marine Biomedical Pty Ltd.",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "680,977 USD",
"type": "total_value",
"unit": "million dollars",
"value": "0.68"
}
] | null |
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso | [
"News"
] | [
"阿斯利康制药"
] | [
"Thermo Fisher Scientific"
] | [
{
"phase": "Approved",
"name": "Tagrisso",
"type": "Drug"
}
] | [
"合作"
] | null | null |
Grand Pharmaceutical (China) Co., Ltd. acquires Jiangsu Shenming Medical Technology Co., Ltd. | [
"NEWS"
] | [
"江苏申命医疗科技有限公司"
] | [
"远大医药"
] | [
{
"name": "江苏申命医疗科技有限公司",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "2260万人民币",
"type": "total_value",
"unit": "million dollars",
"value": "3.54"
}
] | null |
欧林生物与格里菲斯大学GAS项目合作”签约仪式,暨“疫苗开发联合实验室”揭牌仪式在澳大利亚举行 | [
"News"
] | [
"Griffith University"
] | [
"成都欧林生物科技股份有限公司"
] | [
{
"name": "GAS (Group A streptococcus) 疫苗",
"type": "Drug"
}
] | [
"许可"
] | null | null |
Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer | [
"NEWS"
] | [
"Strata Oncology"
] | [
"Pfizer Inc"
] | [
{
"phase": "Approved",
"name": "binimetinib",
"type": "Drug"
},
{
"phase": "Approved",
"name": "axitinib",
"type": "Drug"
},
{
"phase": "Approved",
"name": "encorafenib",
"type": "Drug"
},
{
"phase": "Approved",
"name": "talazoparib tosylate",
"type": "Dru... | [
"临床合作"
] | null | null |
PostEra announces expansion to $610M in their AI drug discovery collaboration with Pfizer | [
"PRNewswire"
] | [
"PostEra"
] | [
"Pfizer"
] | [
{
"name": "Antibody-Drug-Conjugate (ADC) program",
"type": "Drug"
}
] | [
"Collaboration"
] | [
{
"origin_value": "$12M",
"type": "upfront_payment",
"unit": "million dollars",
"value": "12.0000"
}
] | null |
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) | [
"PRNewswire"
] | [
"Rhythm Pharmaceuticals, Inc."
] | [
"PANTHERx® Rare"
] | [
{
"phase": "Approved",
"name": "IMCIVREE",
"type": "Drug"
}
] | [
"Collaboration"
] | null | [
"U.S."
] |
国产首个!公司授权复星旗下公司乙肝-siRNA新药获美国FDA批准直接开展1b期临床 | [
"News"
] | [
"上海赫吉亚生物医药有限责任公司"
] | [
"苏州星曜坤泽生物制药有限公司"
] | [
{
"name": "HT-101注射液",
"type": "Drug"
}
] | [
"许可"
] | null | null |
Granata Bio and IBSA Group Announce Strategic Partnership | [
"PRNewswire"
] | [
"IBSA Institut Biochimique SA"
] | [
"Granata Bio Inc"
] | [
{
"phase": "Approved",
"name": "progesterone , IBSA/Granata Bio",
"type": "Drug"
}
] | [
"许可"
] | null | [
"US"
] |
Alexion Pharmaceuticals is partnering with Complement Pharma to co-develop a C6 complement inhibitor, CP010, for the treatment of neurodegenerative disorders. | [
"News"
] | [
"Complement Pharma"
] | [
"Alexion Pharmaceuticals"
] | [
{
"phase": "Preclinical",
"name": "CP010",
"type": "Drug"
}
] | [
"期权",
"合作"
] | [
{
"origin_value": "15.28百万美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "15.28"
}
] | null |
Eurofarma Laboratórios SA acquires Laboratorio Medipharm | [
"NEWS"
] | [
"Laboratorio Medipharm"
] | [
"Eurofarma Laboratórios SA"
] | [
{
"name": "Laboratorio Medipharm",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "35,999,813 USD",
"type": "total_value",
"unit": "million dollars",
"value": "36.00"
}
] | null |
Université Laval and Glycovax Pharma Enter into an Exclusive Global License Agreement for the Development of Innovative Galectin-3 Inhibitors | [
"PRNewswire"
] | [
"Université Laval"
] | [
"Glycovax Pharma"
] | [
{
"phase": "Discovery",
"name": "Innovative Galectin-3 Inhibitors",
"type": "Drug"
}
] | [
"License"
] | null | [
"Global"
] |
Exelixis, Inc. Signs Wyeth License Pact Worth Up To $157.5 Million | [
"NEWS"
] | [
"Exelixis"
] | [
"Wyeth"
] | [
{
"phase": "Preclinical",
"name": "compounds targeting the farnesoid X receptor",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "147.5百万美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "147.50"
},
{
"origin_value": "10百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "10.00"
}
] | null |
Leadgene Biomedical, Inc. acquires Cytena Bioprocess Solutions | [
"NEWS"
] | [
"Cytena Bioprocess Solutions"
] | [
"Leadgene Biomedical, Inc."
] | [
{
"name": "Cytena Bioprocess Solutions",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics | [
"Biospace"
] | [
"Secarna Pharmaceuticals GmbH & Co. KG"
] | [
"Orbit Discovery Ltd."
] | [
{
"phase": "Discovery-药物发现",
"name": "Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics",
"type": "Drug"
}
] | [
"合作"
] | null | null |
Solvay Pharmaceuticals and Wyeth Pharmaceuticals Sign Agreements to Co-Develop and Co-Commercialize CNS Compounds and Co-Promote EFFEXOR XR | [
"NEWS"
] | [
"Solvay Pharmaceuticals"
] | [
"Wyeth"
] | [
{
"phase": "Phase 3 Clinical",
"name": "bifeprunox",
"type": "Drug"
},
{
"name": "four neuroscience compounds",
"type": "Drug"
}
] | [
"合作"
] | [
{
"origin_value": "145.5百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "145.50"
}
] | null |
Cline Scientific AB acquires Liv Diagnostics | [
"NEWS",
"NEWS"
] | [
"Liv Diagnostics"
] | [
"Cline Scientific AB"
] | [
{
"name": "Liv Diagnostics",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "5,201 USD",
"type": "total_value",
"unit": "million dollars",
"value": "0.01"
}
] | null |
Lyell Immunopharma Completes Acquisition of ImmPACT Bio | [
"NEWS",
"Company_Website",
"GlobeNewswire",
"NEWS"
] | [
"ImmPACT Bio USA Inc."
] | [
"Lyell Immunopharma, Inc."
] | [
{
"name": "ImmPACT Bio USA Inc.",
"type": "Company"
},
{
"phase": "Phase 1 Clinical-临床1期",
"name": "IMPT-314",
"type": "Drug"
},
{
"phase": "Preclinical-临床前",
"name": "an activating TGF-beta Claudin 18.2 CAR T-cell candidate",
"type": "Drug"
}
] | [
"企业收购"
] | [
{
"origin_value": "72,915,000 USD",
"type": "total_value",
"unit": "million dollars",
"value": "72.92"
},
{
"origin_value": "$30 million",
"type": "upfront_payment",
"unit": "million dollars",
"value": "30.0000"
}
] | null |
Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis | [
"PRNewswire"
] | [
"Welichem Biotech"
] | [
"施泰福大药厂"
] | [
{
"phase": "Phase 2 Clinical",
"name": "WBI-1001",
"type": "Drug"
}
] | [
"收购",
"期权"
] | [
{
"origin_value": "27.2百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "27.20"
}
] | [
"Global"
] |
瑞博生物与齐鲁制药签订授权协议推进抗PCSK9小核酸新药的开发与商业化 | [
"NEWS"
] | [
"苏州瑞博生物技术股份有限公司"
] | [
"齐鲁制药有限公司"
] | [
{
"phase": "phase 1 clinical",
"name": "RBD7022",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "7亿元人民币",
"type": "total_value",
"unit": "million dollars",
"value": "98.50"
}
] | [
"中国"
] |
ONO Enters an Agreement with IDAC Theranostics relating to Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody | [
"NEWS"
] | [
"IDAC Theranostics"
] | [
"盐野义制药株式会社"
] | [
{
"phase": "Preclinical",
"name": "IT1208",
"type": "Drug"
}
] | [
"期权"
] | null | null |
Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers | [
"GlobeNewswire"
] | [
"LEO Pharma A/S"
] | [
"Er-Kim"
] | [
{
"phase": "Approved",
"name": "LOQTORZI",
"type": "Drug"
}
] | [
"Collaboration"
] | null | [
"Croatia",
"Estonia",
"Bulgaria",
"Slovenia",
"Lithuania",
"Poland",
"Hungary",
"Romania",
"Slovakia",
"Czechia",
"Latvia"
] |
KLOX Technologies acquires FB Dermatology | [
"NEWS"
] | [
"FB Dermatology"
] | [
"KLOX Technologies"
] | [
{
"name": "FB Dermatology",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
LG Life Sciences agreed to co-develop and commercialize Biosimilar product with Mochida Pharmaceutical | [
"NEWS",
"NEWS"
] | [
"LG Chem"
] | [
"持田制药株式会社"
] | [
{
"phase": "Phase 1 Clinical",
"name": "LBAL",
"type": "Drug"
}
] | [
"合作"
] | null | [
"Japan"
] |
Genovis exercised its call option to acquire the remaining 75% of SEQURNA | [
"Company_Website"
] | [
"SEQURNA AB"
] | [
"Genovis AB"
] | [
{
"name": "SEQURNA AB",
"type": "Company"
}
] | [
"M&A"
] | [
{
"origin_value": "SEK 52.5 million",
"type": "milestone_payment",
"unit": "million dollars",
"value": "5.2347"
}
] | null |
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL | [
"News"
] | [
"Qualigen Therapeutics"
] | [
"University College London"
] | [
{
"phase": "Preclinical",
"name": "AS1411-GNP",
"type": "Drug"
}
] | [
"期权",
"许可"
] | null | [
"Global"
] |
GSK taps Alnylam tech for faster vaccine production | [
"NEWS",
"NEWS"
] | [
"Alnylam"
] | [
"GlaxoSmithKline"
] | [
{
"name": "VaxiRNA platform",
"type": "Technology/Platform"
}
] | [
"License"
] | [
{
"origin_value": "$3.2 million.",
"type": "milestone_payment",
"unit": "million dollars",
"value": "3.2000"
}
] | null |
Sandoz has completed the acquisition of GSK's cephalosporin antibiotics business | [
"News"
] | [
"山德士制药有限公司"
] | [
"葛兰素史克制药"
] | [
{
"phase": "Approved",
"name": "Zinacef",
"type": "Drug"
},
{
"phase": "Approved",
"name": "Fortum",
"type": "Drug"
},
{
"phase": "Approved",
"name": "Zinnat",
"type": "Drug"
}
] | [
"许可"
] | null | null |
CheckmAb announced the successful achievement of the second milestone in the collaboratton with Boehringer Ingelheim | [
"NEWS"
] | [
"CheckmAb S.r.l."
] | [
"Boehringer Ingelheim"
] | [
{
"phase": "Discovery",
"name": "monoclonal anttbody (mAb) for cancer immunotherapy",
"type": "Drug"
}
] | [
"License"
] | [
{
"origin_value": "EUR 240 million",
"type": "milestone_payment",
"unit": "million dollars",
"value": "248.0387"
}
] | null |
Guangdong Vtr Bio-Tech takes a minority stake in Changsha World-Way Biotech, Inc. | [
"NEWS",
"NEWS"
] | [
"Changsha World-Way Biotech, Inc."
] | [
"Guangdong Vtr Bio-Tech"
] | [
{
"name": "Changsha World-Way Biotech, Inc.",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "12,295,524 USD",
"type": "total_value",
"unit": "million dollars",
"value": "12.30"
}
] | null |
Dimerix Bioscience Pty Ltd entered into a second research program with Takeda Cambridge Limited | [
"NEWS"
] | [
"Dimerix Bioscience Pty Ltd"
] | [
"Takeda Cambridge Limited"
] | [
{
"phase": "Discovery",
"name": "new drugs targeting GPCRS",
"type": "Drug"
}
] | [
"Collaboration"
] | null | null |
圣和药业携手卡提医学进军细胞治疗领域 | [
"NEWS"
] | [
"南京卡提医学科技有限公司"
] | [
"南京圣和药业股份有限公司"
] | [
{
"name": "CAR-T细胞构建的专业技术平台",
"type": "Technology/Platform"
}
] | [
"合作"
] | null | null |
亚宝药业携手印度鲁宾制药拓展中国儿科产品市场 | [
"News"
] | [
"印度鲁宾有限公司"
] | [
"亚宝药业集团股份有限公司"
] | [
{
"name": "儿科用药",
"type": "Drug"
}
] | [
"许可"
] | null | [
"中国"
] |
Quartz Bio acquires Solve Inc | [
"NEWS"
] | [
"Solve Inc"
] | [
"Quartz Bio",
"Precision Medicine Group"
] | [
{
"name": "Solve Inc",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Q-Med AB Agrees to Be Acquired by Galderma Pharma S.A. for $970 Million | [
"NEWS"
] | [
"Q-Med AB"
] | [
"高德美制药"
] | [
{
"name": "Q-Med AB",
"type": "Company"
}
] | [
"企业收购"
] | [
{
"origin_value": "750.96百万美元",
"type": "total_value",
"unit": "million dollars",
"value": "750.96"
}
] | null |
Maverix Medical LLC acquires Cirrus Bio | [
"NEWS"
] | [
"Cirrus Bio"
] | [
"Hologic, Inc.",
"Kohlberg Kravis Roberts & Co. LP",
"Maverix Medical LLC",
"Ajax Health LLC"
] | [
{
"name": "Cirrus Bio",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 | [
"NEWS"
] | [
"Kate Therapeutics"
] | [
"安斯泰来制药"
] | [
{
"phase": "临床前",
"name": "KT430",
"type": "Drug"
}
] | [
"许可"
] | null | null |
Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals | [
"News"
] | [
"Vertex Pharmaceuticals"
] | [
"Trek Therapeutics"
] | [
{
"phase": "Phase 2 Clinical",
"name": "VX-222",
"type": "Drug"
},
{
"phase": "Phase 2 Clinical",
"name": "VX-497",
"type": "Drug"
}
] | [
"许可"
] | null | [
"Global"
] |
中国科学院上海药物研究所与海和药物合作开展溴结构域蛋白(BRD4)抑制剂的合作研究 | [
"News"
] | [
"上海海和药物研究开发股份有限公司"
] | [
"中国科学院上海药物研究所"
] | [
{
"phase": "Preclinical",
"name": "HH3567",
"type": "Drug"
}
] | [
"合作"
] | null | null |
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe | [
"News",
"News"
] | [
"Y-mAbs Therapeutics"
] | [
"WEP Clinical"
] | [
{
"phase": "Approved",
"name": "DANYELZA®",
"type": "Drug"
}
] | [
"许可"
] | null | [
"欧洲"
] |
Tervetuloa Orionin uutishuoneeseen, josta löydät uusimmat tiedotteet ja ajankohtaiset artikkelit. | [
"News"
] | [
"CuraTeQ Biologics"
] | [
"芬兰奥利安集团"
] | [
{
"phase": "Phase 3 Clinical",
"name": "CuraTeQ’s biosimilars",
"type": "Drug"
}
] | [
"合作",
"许可"
] | null | null |
Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program | [
"NEWS"
] | [
"Amira Pharmaceuticals"
] | [
"葛兰素史克制药"
] | [
{
"name": "FLAP inhibitors",
"type": "Drug"
},
{
"name": "AM103",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "425百万美元",
"type": "upfront_payment",
"unit": "million dollars",
"value": "425.00"
}
] | [
"Global"
] |
SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES | [
"NEWS"
] | [
"University of Texas Medical Branch at Galveston"
] | [
"Sorrento Therapeutics Inc"
] | [
{
"phase": "preclinical",
"name": "ACE-MAB , Mabpharm/Sorrento Therapeutics",
"type": "Drug"
}
] | [
"合作"
] | null | null |
IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer | [
"PRNewswire"
] | [
"IsomAb Ltd"
] | [
"Pfizer"
] | [
{
"name": "ISM-001",
"type": "Drug"
}
] | [
"collaboration"
] | null | null |
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc | [
"GlobeNewswire"
] | [
"BIOASIS TECHNOLOGIES INC."
] | [
"Midatech Pharma plc"
] | [
{
"name": "Bioasis Technologies",
"type": "Company"
}
] | [
"企业收购"
] | null | null |
GARDP and BioVersys will sign an MOU to collaborate on the development of antibiotics, including BV-100, for treating paediatric bacterial infections. | [
"NEWS"
] | [
"Global Antibiotic Research and Development Partnership"
] | [
"BioVersys AG"
] | [
{
"phase": "Preclinical",
"name": "BV-100",
"type": "Drug"
}
] | [
"合作"
] | null | null |
Intec Pharma Announces Research Collaboration Agreement With Merck | [
"News"
] | [
"Intec Pharma"
] | [
"默沙东制药"
] | [
{
"name": "Accordion Pill ® (AP) platform",
"type": "Technology/Platform"
}
] | [
"合作"
] | null | null |
Crescita Announces Licensing Agreement for Pliaglis® in China | [
"NEWS"
] | [
"Crescita Therapeutics Inc"
] | [
"Juyou Bio-Technology Co Ltd"
] | [
{
"phase": "Approved",
"name": "lidocaine + tetracaine , Nuvo",
"type": "Drug"
}
] | [
"许可"
] | [
{
"origin_value": "2.8 million 美元",
"type": "milestone_payment",
"unit": "million dollars",
"value": "2.80"
},
{
"origin_value": "2.925 million 美元",
"type": "total_value",
"unit": "million dollars",
"value": "2.93"
},
{
"origin_value": "0.125 million 美元",
"type": "upf... | [
"China"
] |
End of preview. Expand in Data Studio
🤝 Dataset Summary
Pharmaceutical licensing and deal intelligence records covering 1,000 transactions. Each record captures the deal structure, involved organizations, financial terms, and asset details, sourced from news and company disclosures.
🚀 Key Features
- Deal Structure:
deal_typeclassifies transaction type (license, acquisition, collaboration, etc.) with multilingual labels. - Financial Terms:
deal_valueprovides structured breakdown of payment types (upfront, milestone) with normalized USD values (~34.5% of records). - Organizational Mapping:
principle_organdpartner_orgidentify both sides of each transaction. - Asset Linkage:
deal_projectlinks deals to specific drugs or programs by name and type. - Territory Coverage:
territory_includedspecifies geographic rights where disclosed (~33.8% of records).
💻 Quick Start & MCP Integration
from datasets import load_dataset
dataset = load_dataset("your-org/drug-deals", split="train")
record = dataset[0]
print(record["deal_title"])
# Output: 'GSK exercises option on Anacor\'s novel antibiotic for the treatment of gram-negative infections'
print(record["principle_org"])
# Output: ['Anacor Pharmaceuticals']
print(record["deal_value"][0]["value"])
# Output: '15.00' (million dollars, upfront payment)
- Downloads last month
- 30